PMDA drug package insert
ベポタスチンベシル酸塩錠5mg「タナベ」
PMDA Prescription drug · ニプロ株式会社 · package insert Apr 1, 2025
Key facts
| Brand names | ベポタスチンベシル酸塩錠5mg「タナベ」, ベポタスチンベシル酸塩錠10mg「タナベ」, ベポタスチンベシル酸塩OD錠5mg「タナベ」, ベポタスチンベシル酸塩OD錠10mg「タナベ」 |
|---|---|
| Nonproprietary names | ベポタスチンベシル酸塩 |
| Companies | 製造販売元／ニプロ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 選択的ヒスタミンH1受容体拮抗・アレルギー性疾患治療剤 |
| Therapeutic category codes | 87449 |
| YJ codes | 4490022F1046, 4490022F2042, 4490022F3030, 4490022F4037 |
| Approval numbers | 22800AMX00539, 22800AMX00538, 22800AMX00537, 22800AMX00536 |
| Package insert edition | 第1版 |
| Package insert date | Apr 1, 2025 |
| PMDA document key | 530100_4490022F1046_2 |
| PMDA company code | 530100 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: